Immunovant
IMVT
181 hedge funds and large institutions have $2.57B invested in Immunovant in 2023 Q3 according to their latest regulatory filings, with 61 funds opening new positions, 64 increasing their positions, 44 reducing their positions, and 24 closing their positions.
300% more funds holding in top 10
Funds holding in top 10: 3 → 12 (+9)
154% more first-time investments, than exits
New positions opened: 61 | Existing positions closed: 24
144% more capital invested
Capital invested by funds: $1.05B → $2.57B (+$1.52B)
45% more repeat investments, than reductions
Existing positions increased: 64 | Existing positions reduced: 44
23% more funds holding
Funds holding: 147 → 181 (+34)
8.66% more ownership
Funds ownership: 42.53% → 51.19% (+8.7%)
46% less call options, than puts
Call options by funds: $136M | Put options by funds: $252M
Top Buyers
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$56.4M |
| 2 |
DGM
Darwin Global Management
St. Helier,
Jersey
|
+$41.1M |
| 3 |
PA
Perceptive Advisors
New York
|
+$29.2M |
| 4 |
FAM
Fred Alger Management
New York
|
+$26.4M |
| 5 |
AC
Armistice Capital
New York
|
+$23.4M |
Top Sellers
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
201
Barclays
London,
United Kingdom
| – | -$51.7K | -2,286 | Closed |
|
|
IPW
202
Impact Partnership Wealth
Marietta,
Georgia
| – | -$1.78K | -94 | Closed |
|
|
NC
203
NewSquare Capital
Newtown Square,
Pennsylvania
| – | -$949 | -50 | Closed |
|
|
C
204
Covestor
London,
United Kingdom
| – | -$45 | -2 | -18% |
|
IMVT Hedge Fund Activity: Q3 2023 in Review
181 of the 6,301 institutional investors tracked by Wall St. Rank reported a position in Immunovant (IMVT) for Q3 2023, worth a combined $2.57B — up 144% from $1.05B a quarter earlier.
Buyers outnumbered sellers: 61 funds opened new IMVT positions and 24 closed out — a net gain of 37 holders — while 64 added to existing stakes and 44 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $56.4M. The largest seller was Deep Track Capital, cutting an estimated $59.3M.
- 181 institutional investors held Immunovant (IMVT) as of Q3 2023, up from 147 in Q2 2023.
- Funds reported $2.57B of Immunovant stock for Q3 2023, up 144% quarter-over-quarter.
- 61 funds opened new Immunovant positions in Q3 2023 and 24 closed out, a net change of +37 holders.
- The largest Immunovant buyer in Q3 2023 was Fidelity Investments, an estimated $56.4M added.
- The largest Immunovant seller in Q3 2023 was Deep Track Capital, an estimated $59.3M sold.
Based on aggregated 13F filings for Q3 2023.